Please ensure Javascript is enabled for purposes of website accessibility

Cannabis Company MediPharm Labs Secures Australian Import License

By Eric Volkman - Jan 31, 2020 at 5:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It will be one of several supplying that country's medical marijuana market.

MediPharm Labs (MEDIF 0.18%) now has the green light to begin shipping product to Australia. The Canadian cannabis extraction specialist announced Friday it has received an import license from that country's Department of Health.

This permit allows MediPharm to ship cannabis, cannabinoids, and resin from Canada to Australia. These goods can be used to make finished products such as tinctures. 

Sydney Australia from the water.

Image source: Getty Images

Australia made medical cannabis legal in 2016, and since then, a clutch of companies both domestic and foreign has emerged to supply product to qualified patients. The country still bars recreational consumption at the federal level, although somewhat controversially, its Capital Territory (which includes Canberra and its surrounding townships) legalized it last year within its borders.

In its press release heralding the receipt of the license, MediPharm said it "is an important milestone as we continue to build a multi-jurisdictional [Good Manufacturing Practices]-certified pharmaceutical-quality platform to serve the world's most attractive medical cannabis markets."

In Australia, cannabis companies must earn Good Manufacturing Practices (GMP) certification in order to sell their products.

The import license news will be welcomed by shareholders, as other recent developments with MediPharm haven't been entirely positive. Last week, it revealed that it is suing an unnamed licensed cannabis producer in Canada for breach of contract, alleging that this party owes it nearly 10 million Canadian dollars ($7.6 million) for product MediPharm supplied. It was subsequently discovered that the  company being sued is HEXO. Perhaps that issue is still weighing on investors' minds, as the marijuana stock closed Friday down by nearly 6%.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MediPharm Labs Corp. Stock Quote
MediPharm Labs Corp.
MEDIF
$0.06 (0.18%) $0.00
HEXO Stock Quote
HEXO
HEXO
$0.23 (-3.34%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.